FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person* Sukhija Remy (Last) (First) (Middle) C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 200					2. Issuer Name and Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS, INC. [MDGL] 3. Date of Earliest Transaction (Month/Day/Year) 02/22/2021						C. (Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Commercial Officer					
(Street) WEST CONSHO	OHOCKEN (S	PA tate)	19428 (Zip)	4.	If Ame	endment, I	Date	of Original F	iled	(Month/Da	ıy/Year)	Line	X Form f	iled by One I	Reporting	Persor	.
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			nsaction	Execution Date,			3. Transac Code (In 8)	tion	4. Securi	ties Acquire I Of (D) (Ins	ed (A) or tr. 3, 4 and	5. Amou Securitie Beneficia	nt of (s) (s) (s) (s) (s) (s) (s) (s) (s)	6. Ownersh Form: Dire (D) or Indire (I) (Instr. 4)	ct C	. Nature of Indirect Beneficial Ownership Instr. 4)	
(e.g., pt 1. Title of					tansaction of Derivative			Expiration Date of Securi (Month/Day/Year) Underlyin Derivativ				d Amount des	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following	Owner Form Direct or Inc	t (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	•			Code	v	Dispose of (D) (II 3, 4 and	nstr.	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		Reported Transaction (Instr. 4)	1,,,	,	
Stock Option (Right to Buy)	\$119.49	02/22/2021		A		24,000		(1)	02	2/22/2031	Common Stock	24,000	\$0.00	24,000	1)	

Explanation of Responses:

1. The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

** As attorney-in-fact for Reporting Person

/s/ Brian J. Lynch**

02/23/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.